Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
American Regent Inc. is managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 3 distinct examiners, which means that every active case is being reviewed by a different person. This variety of examiners can provide a range of perspectives on the company's pharmaceutical claims. The portfolio is spread across 2 distinct art units, showing some departmental diversity within the patent office.
BAEK, BONG-SOOK is the busiest examiner, with 1 busiest examiner pending office action. This 1 action represents 1 of the 3 pending office actions total. With 3 distinct examiners involved, no single individual's examination style dominates the current prosecution landscape. This distribution across 2 distinct art units suggests that the company's biotech innovations are being evaluated by multiple specialized groups. This variety in both examiners and art units provides a broader base of feedback for the company's intellectual property strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAEK, BONG-SOOK | 1 | 41.7% | +69.9% |
| KASSA, TIGABU | 1 | 36.7% | +27.9% |
| CHEN, PO-CHIH | 1 | 74.2% | +14.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18686305 | IRON COMPOSITIONS AND METHODS OF MAKING AND USING THEM | KASSA, TIGABU | 62d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18686305 | IRON COMPOSITIONS AND METHODS OF MAKING AND USING THEM | KASSA, TIGABU | 62d |
| 18955379 | TRACE ELEMENT COMPOSITIONS, METHODS OF MAKING AND USE | BAEK, BONG-SOOK | — |
| 17626936 | Equine Esomeprazole Formulations and Methods of Use | CHEN, PO-CHIH | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18955379 | TRACE ELEMENT COMPOSITIONS, METHODS OF MAKING AND USE | BAEK, BONG-SOOK | — | §102§103§112DP | Non-Final OA | — | Pending | Nov 21, 2024 |
| 18686305 | IRON COMPOSITIONS AND METHODS OF MAKING AND USING THEM | KASSA, TIGABU | 1615 | §102§103 | Non-Final OA | 62d | Pending | Feb 23, 2024 |
| 17626936 | Equine Esomeprazole Formulations and Methods of Use | CHEN, PO-CHIH | 1621 | §112 | Non-Final OA | — | Pending | Jan 13, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial